文献速递腹部技术与安全CT

多靶点粪便DNA与CT结肠成像在结直肠癌无创筛查中的诊断效能

Diagnostic Performance of Multitarget Stool DNA and CT Colonography for Noninvasive Colorectal Cancer Screening.
PubMed 文献 · Radiology · 2020-08-11

该回顾性队列研究在单一中心比较了多靶点粪便DNA(mt-sDNA)与CT结肠成像筛查结直肠癌的结果。mt-sDNA阳性者后续光学结肠镜随访率仅13.1%,其进展期肿瘤检出率2.7%低于6 mm阈值CT结肠成像的5.0%(P<.001),结直肠癌检出率两者相似(0.23% vs 0.31%,P=.43)。

要点

  • 6 mm阈值CT结肠成像对进展期肿瘤检出率5.0%,高于mt-sDNA的2.7%(P<.001)。
  • mt-sDNA与6 mm阈值CT结肠成像的结直肠癌检出率分别为0.23%和0.31%,差异无统计学意义(P=.43)。
  • 10 mm阈值CT结肠成像阳性预测值最高:任何≥6 mm肿瘤84.5%,进展期肿瘤75.2%,结直肠癌5.2%。

核心结论

  • CT结肠成像筛查的进展期肿瘤检出率高于多靶点粪便DNA,两者结直肠癌检出率相似。

研究设计与样本

  • 回顾性队列研究,纳入接受临床mt-sDNA筛查的无症状成人3987例(平均年龄64岁±9,女性2567例)和接受CT结肠成像筛查者9656例(平均年龄57岁±8,女性5200例),以光学结肠镜及组织病理学为参考标准。

关键影像表现/征象

  • mt-sDNA、6 mm阈值CT结肠成像、10 mm阈值CT结肠成像的阳性率分别为15.2%、16.4%和6.7%。
  • mt-sDNA、6 mm阈值CT结肠成像、10 mm阈值CT结肠成像阳性者光学结肠镜随访率分别为13.1%、12.3%和5.9%。

诊断标准与关键数值

  • mt-sDNA对任何≥6 mm肿瘤、进展期肿瘤、结直肠癌的阳性预测值分别为54.2%、22.7%、1.9%。
  • 6 mm阈值CT结肠成像对任何≥6 mm肿瘤、进展期肿瘤、结直肠癌的阳性预测值分别为76.8%、44.3%、2.7%。
  • 10 mm阈值CT结肠成像对任何≥6 mm肿瘤、进展期肿瘤、结直肠癌的阳性预测值分别为84.5%、75.2%、5.2%。
  • mt-sDNA与CT结肠成像上述阳性预测值比较P<.001,但6 mm阈值CT结肠成像的结直肠癌阳性预测值除外。
  • mt-sDNA与6 mm阈值CT结肠成像的进展期肿瘤总检出率分别为2.7%和5.0%(P<.001),结直肠癌检出率分别为0.23%和0.31%(P=.43)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BackgroundMultitarget stool DNA (mt-sDNA) screening has increased rapidly since simultaneous approval by the U.S. Food and Drug Administration and Centers for Medicare and Medicaid Services in 2014, whereas CT colonography screening remains underused and is not covered by Centers for Medicare and Medicaid Services.PurposeTo report postapproval clinical experience with mt-sDNA screening for colorectal cancer (CRC) and compare results with CT colonography screening at the same center.Materials and MethodsIn this retrospective cohort study, asymptomatic adults underwent clinical mt-sDNA screening during a 5-year interval (2014-2019). Electronic medical records were searched to verify test results and document subsequent optical colonoscopy and histopathologic findings. A similar analysis was performed for CT colonography screening during a 15-year interval (2004-2019), with consideration of thresholds for positivity of both 6-mm and 10-mm polyp sizes. χ2 or two-sample t tests were used for group comparisons.ResultsA total of 3987 asymptomatic adult patients (mean age, 64 years ± 9 [standard deviation]; 2567 women) underwent mt-sDNA screening and 9656 patients (mean age, 57 years ± 8; 5200 women) underwent CT colonography. Test-positive rates for mt-sDNA and for 6-mm- and 10-mm-threshold CT colonography were 15.2%, 16.4%, and 6.7%, respectively. Optical colonoscopy follow-up rates for positive results of mt-sDNA and 6-mm- and 10-mm-threshold CT colonography were 13.1%, 12.3%, and 5.9%, respectively. Positive predictive values (PPVs) for any neoplasm 6 mm or greater, advanced neoplasia, and CRC for mt-sDNA were 54.2%, 22.7%, and 1.9% respectively; for 6-mm-threshold CT colonography, PPVs were 76.8%, 44.3%, and 2.7%; for 10-mm-threshold CT colonography, PPVs were 84.5%, 75.2%, and 5.2%, respectively (P < .001 for mt-sDNA vs CT colonography for all except 6-mm CRC at CT colonography). For mt-sDNA versus 6-mm-threshold CT colonography, overall detection rates for advanced neoplasia were 2.7% and 5.0%, respectively (P < .001); corresponding detection rates for CRC were 0.23% and 0.31%, respectively (P = .43).ConclusionThe detection rates of advanced neoplasia at CT colonography screening were greater than those of multitarget stool DNA. Detection rates were similar for colorectal cancer.© RSNA, 2020See also the editorial by Yee in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Pickhardt PJ, Graffy PM, Weigman B, et al. Diagnostic Performance of Multitarget Stool DNA and CT Colonography for Noninvasive Colorectal Cancer Screening. Radiology. 2020. PMID: 32779997. doi:10.1148/radiol.2020201018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。